Makale Arama

Aim: It was aimed to compare with healthy volunteers the changes in heat shock protein (HSP) 90 alpha and vitamin levels during exacerbation and remission periods in our patients with familial Mediterranean fever (FMF), to research whether these molecules will benefit in control of FMF exacerbation and prevention of amyloid accumulation, and also to investigate the relationship of these molecules with FMF gene mutations.

Patients and Methods: HSP 90 alpha, vitamin A, vitamin B 12, vitamin D, vitamin E and folic acid levels were studied in 30 patients with AAA diagnosed in our hospital's pediatric nephrology department during the exacerbation and remission periods and 30 healthy volunteers. The results were compared statistically.

Results: In our series, 19 (63.3%) of the patients were male, 11 (36.7%) were female, with a mean age of 11 years. The most common presenting complaint was abdominal pain (n=19; 63.3%) after fever and only high fever was found to be present in five (16.7%) patients. The most common genetic mutation was M694V (n=14; 46.7%), whereas no mutation was detected in five (16.7%) patients. Although HSP 90 alpha was the highest in the exacerbation group and the lowest in the remission group, there was no significant difference between the groups. Vitamin B12 was significantly different between the groups and the highest value was in the control group. Vitamin D was significantly different between the exacerbation and the remission groups and the highest value was in the exacerbation group. In addition, vitamin D levels were significantly higher in boys. There was no significant difference between vitamin A, vitamin E and folic acid levels. FMF gene mutations did not affect HSP 90 alpha and vitamin levels.

Conclusion: Our findings showed that serum HSP 90 alpha, vitamin D, vitamin E and folic acid levels were normal in AAA, but vitamin B12 and vitamin A levels were low during exacerbation and remission. However, we think that prospective studies including larger series should be performed about the subject.

Aim: JAK2 V617F mutation is determined in 95% of polycythemia vera (PV) patients. However, this test is a high-cost and time-consuming examination. In this study, a rapid, inexpensive and easily available test that can be used in addition to JAK2 V617F mutation is planned to exclude secondary polycythemia (SP).

Patients and Methods: A total of 39 PV patients and 51 SP patients, who were diagnosed according to 2016 diagnostic criteria of World Health Organization, have been included in this study. Demographics, physical examination findings and laboratory results of patients have been determined. A statistical analysis was performed between these two groups.

Results: In PV group, serum vitamin B12 level, erythrocyte count, leukocyte count, neutrophil count, platelet count and lactate dehydrogenase levels were determined to be statistically significantly higher than SP group. Serum vitamin B12 level above 343 pg/mL has been determined as the threshold value for the differentiation of PV from SP.

Conclusion: High serum vitamin B12 level was determined to be associated with PV. However, there is a need for prospective studies performed with larger patient series supporting the data obtained in this study in order for serum vitamin B12 level to be used in the differential diagnosis of primary and secondary polycythemia.

\r\n Introduction: Multipl myeloma is a disease of unknown pathogenesis. Although there was a different

\r\n hypotheses on the subject, recently mutations in the pathway of apoptosis come to the fore. PUMA may play a role in apoptosis, bound or

\r\n unbound p53. The role is regulated by various signals of transcription factors. In this study; the expressions of p53 and PUMA in bone marrow hematopoetic cells of

\r\n have been worked and the relationship between myeloma pathogenesis with p53- PUMA was

\r\n searched.

\r\n Method: The expression of p53 and PUMA was evaluated using immunohistochemistry. The

\r\n procedure was carried out using specific antibodies against p53 and PUMA. Bone marrow

\r\n biopsies of MM patients at the time of diagnosis (n=31) were included in the study group.

\r\n Bone marrow biopsies from individuals who had normal hematopoiesis (n=12) were included

\r\n as control. After staining, strength was calculated of each positively staining

\r\n cells.

\r\n Findings: The percentage of cells showing PUMA expression was significantly higher in

\r\n bone marrows of MM patients as compared to normal bone marrow samples (p=0.000). We

\r\n found a correlation between the percentage of plasma cells with staining prevalence of

\r\n PUMA, but it was not statistically significant (p=0.385). There was no correlation between

\r\n the stage of the disease with PUMA expression.

\r\n Results: Our results showed that specially PUMA expression is significantly higher in bone

\r\n marrow cells of MM patients compared to healthy controls. Higher positivity of PUMA

\r\n suggested that, PUMA induced nongenotoxic reasons at the time of diagnosis. The lack of

\r\n p53 and PUMA positivite suggests that, apoptosis play a role in myeloma pathogenes

Purpose: It was aimed to present the clinical and functional results of the patients who underwent tumor resection and endoprosthetic reconstruction due to malignant tumor around the elbow.

Methods: 14 patients who underwent tumor resection and endoprosthetic reconstruction due to malignant tumor in the elbow circumference between 2011-2018 in our clinic were included in the study. While 4 of the patients were primary tumors (1 fibromixoid sarcoma, 1 leimyosarcoma, 1 multiple myeloma and 1 ewing sarcoma), 10 were distant organ metastases (4 breast cancer, 3 lung cancer, 1 stomach cancer, 1 renal cell cancer and 1 thyroid cancer). Musculoskeletal Tumour Society (MSTS) score and Mayo elbow performance score (MEPS) and survival were evaluated.

Results: The minimum follow-up period of the patients was 7 months, and the maximum follow-up period was 55 months. The mean MEPS score of the patients was 67.5 ± 12.0 (range, 45-90), and the mean of the MSTS score was 19.4 ± 2.3 (range, 16-24). Recurrence occurred at follow-up in 3 patients and exitus at follow-up in 7 patients. In this study, the median survival time of the patients was 44 months. The 1-year survival rate was 70.1% while the 3-year survival rate was 54.5%.

Conclusion: Pain and functional results are satisfactory in patients who undergo tumor resection and endoprosthetic reconstruction due to malignant tumor around the elbow. In the future, studies with larger patient series are needed.